NCT02619669: Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer

NCT02619669
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER++
Other Mutations: HER2+-low
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must be ER++ and HER2+-low, defined as IHC 0-1+
Exclusions: 
https://ClinicalTrials.gov/show/NCT02619669

Comments are closed.

Up ↑